17 citations
,
January 2020 in “The World Journal of Men's Health” This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.
4 citations
,
May 2018 in “BMC Musculoskeletal Disorders” This study found that dutasteride is not associated with an increased risk of osteoporosis or fractures in older men compared to finasteride, suggesting dutasteride does not adversely affect bone health.
22 citations
,
August 2014 in “Clinical endocrinology” This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.